Oasmia Pharmaceutical AB (publ) (Oasmia) has carried out a new issue of shares with preferential rights for Oasmia’s shareholders. Through the rights issue, which was oversubscribed, Oasmia will receive proceeds amounting to approximately SEK 399 million before costs relating to the rights issue.

Oasmia is an integrated pharmaceutical company that develops, manufactures and markets an enhanced generation of drugs within human and veterinary oncology. 

ABG Sundal Collier is the financial advisor to Oasmia and Baker McKenzie is the legal advisor to ABG Sundal Collier in connection with the rights issue. Baker McKenzie's team consist of Joakim Falkner Stefan Balazs and Ian Gulam.

Explore Our Newsroom